Ouch: Eliem’s pain drug fails second PhII trial, gets scrapped
In April, Eliem Therapeutics’ lead candidate, ETX-810, failed a Phase II study for diabetic nerve pain, buckling the greater Seattle-based biotech’s stock by over half. At the time, Eliem CEO and president Bob Azelby called the results “unambiguous” in not providing benefit for diabetic nerve pain (DPNP).
But Eliem had another shot with its pain drug — a second Phase II trial for a form of back pain called lumbosacral radicular pain (LSRP), known more commonly as sciatica. This morning Eliem announced that its lead candidate had failed in that trial too, and that it would be dropping the drug altogether.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.